Business Context and Reporting Period
This Form 8-K is filed by Tivic Health Systems, Inc. (not Valion Bio, Inc.) on March 18, 2025. The report discloses the entry into a material definitive agreement and references financial results for the year ended December 31, 2024, which were released on March 21, 2025.
Key Financial Metrics and Capital Structure
The filing details a new financing facility rather than historical financial performance metrics.
- Financing Facility: Entered into an Equity Purchase Agreement with Mast Hill Fund, L.P. for up to $25,000,000 (Maximum Commitment Amount).
- Term: 24 months, expiring March 18, 2027, unless terminated earlier.
- Pricing Mechanism: Shares sold at 95% of the lowest Volume Weighted Average Price (VWAP) during a 5-day pricing period following a Put Notice.
- Transaction Limits: Minimum sale of $50,000; maximum sale of $500,000 per Put Notice. Sales cannot exceed 100% of the average daily trading volume.
- Ownership Caps: Investor subject to a 4.99% beneficial ownership blocker. Total issuance capped at 19.99% of pre-transaction outstanding shares without shareholder approval.
- Commitment Shares: Issued 29,800 restricted shares to the Investor as upfront consideration.
- Placement Agent Fees: Craft Capital Management LLC to receive a 3.0% commission on gross proceeds from each sale.
Note: The filing text does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels. These metrics are referenced as being contained in a separate press release (Exhibit 99.1) but are not detailed in this document.
Material Changes and Unusual Items
The primary material change is the establishment of the "Put" facility, providing the Company with discretionary access to capital. This represents a shift in liquidity strategy, allowing the Company to raise funds on its own timeline subject to market conditions. The issuance of 29,800 Commitment Shares constitutes an unregistered sale of equity securities exempt under Section 4(a)(2) and Rule 506(b).
Guidance, Outlook, and Risks
Outlook and Management Commentary: Actual sales under the agreement depend on market conditions, stock price, and management's determination of funding needs. The Company retains the right to terminate the agreement at any time.
Risks and Contingencies:
- Dilution Risk: Issuance of shares up to 19.99% (or more with approval) will dilute existing shareholders.
- Pricing Risk: The 95% of lowest VWAP pricing formula may result in shares being sold at a discount to current market prices.
- Market Volatility: Sales are limited by trading volume caps, which could restrict capital raising during periods of low liquidity.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from estimates due to known and unknown risks.
Investor Verification Checklist
- Verify the full text of the Equity Purchase Agreement (Exhibit 10.1) for specific conditions precedent and termination clauses.
- Review the Press Release (Exhibit 99.1) for the actual revenue, net loss, and cash position for the year ended December 31, 2024, as these figures are not in the 8-K body.
- Confirm the current share count to calculate the exact dilution impact of the 19.99% issuance cap.
- Monitor the Registration Rights Agreement (Exhibit 10.2) to ensure the registration statement for the Put Shares and Commitment Shares is filed and declared effective within the required 90-day window.
- Check for any short sale activity by the Investor, as they have covenanted against it, though enforcement relies on disclosure.